ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 185 filers reported holding ASCENDIS PHARMA A/S in Q3 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,785,000 | -97.8% | 20,000 | -97.4% | 0.01% | -98.0% |
| Q1 2023 | $82,678,414 | +80.7% | 771,110 | +105.8% | 0.26% | +64.1% |
| Q4 2022 | $45,763,332 | +15.4% | 374,710 | -2.5% | 0.16% | -1.3% |
| Q3 2022 | $39,672,000 | +1119.2% | 384,200 | +997.7% | 0.16% | +1028.6% |
| Q2 2022 | $3,254,000 | -78.4% | 35,000 | -68.8% | 0.01% | -76.7% |
| Q4 2021 | $15,094,000 | +2.6% | 112,200 | +21.5% | 0.06% | -7.7% |
| Q3 2021 | $14,713,000 | +31.4% | 92,309 | +8.5% | 0.06% | +30.0% |
| Q2 2021 | $11,195,000 | +148.2% | 85,100 | +143.1% | 0.05% | +138.1% |
| Q1 2021 | $4,511,000 | -35.1% | 35,000 | -16.1% | 0.02% | -38.2% |
| Q4 2020 | $6,955,000 | -14.9% | 41,700 | -42.6% | 0.03% | -48.5% |
| Q1 2020 | $8,175,000 | – | 72,600 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |